Stock listing

NASDAQ:PHIO Phio Pharmaceuticals Corp. Stock

Home listing (NASDAQ) of Phio Pharmaceuticals Corp.

Follow Phio Pharmaceuticals Corp. into a list and get an email when it puts out news.

Share price · NASDAQ:PHIO

$0.656 USD -0.064 (-8.9%)

Close on Nov 20, 2026

Past year -44.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.640 – $0.731 USDNov 20, 2026
Volume
145,405 sharesNov 20, 2026
Market cap
$7.84M USDAt the close on Nov 20, 2026 · price × 11.95M shares outstanding
52-week range
$0.640 – $1.880 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$111,364 USDMedian day 86,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Phio Pharmaceuticals Corp. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PHIO · Home$0.656 USD-0.064 (-8.9%)145,405$0.726$0.731$0.640$0.720Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.656-0.064-8.9%$0.726$0.731$0.640145,405
$0.720+0.003+0.4%$0.730$0.767$0.70357,935
$0.717-0.035-4.7%$0.750$0.750$0.70265,248
$0.752-0.019-2.4%$0.767$0.771$0.72076,758
$0.771-0.041-5.0%$0.799$0.840$0.75063,048
$0.812-0.001-0.2%$0.846$0.860$0.78570,919
$0.813-0.001-0.1%$0.821$0.860$0.80281,317
$0.814-0.026-3.1%$0.800$0.860$0.79055,439
$0.840+0.039+4.8%$0.800$0.850$0.753107,228
$0.801+0.001+0.2%$0.780$0.830$0.75075,614
$0.800-0.070-8.0%$0.884$0.884$0.799115,968
$0.870-0.033-3.7%$0.885$0.909$0.86259,630
$0.903+0.023+2.6%$0.870$0.920$0.87033,012
$0.880+0.020+2.3%$0.869$0.900$0.86028,820
$0.860-0.003-0.3%$0.860$0.877$0.85066,656
$0.863-0.054-5.9%$0.880$0.915$0.86325,030
$0.917+0.026+2.9%$0.891$0.917$0.85012,499
$0.891+0.041+4.8%$0.869$0.920$0.85068,029
$0.850-0.002-0.2%$0.883$0.883$0.85042,114
$0.852-0.021-2.4%$0.859$0.900$0.85130,700
$0.873-0.022-2.5%$0.895$0.915$0.87053,600
$0.895+0.003+0.3%$0.908$0.920$0.863100,300
$0.892+0.023+2.6%$0.859$0.910$0.85960,600
$0.869-0.002-0.2%$0.870$0.890$0.85190,700
$0.871-0.055-5.9%$0.910$0.943$0.87191,100
$0.926-0.024-2.5%$0.900$0.980$0.900135,800
$0.950+0.015+1.6%$0.910$0.950$0.890132,200
$0.935+0.013+1.4%$0.960$0.960$0.92069,200
$0.922-0.057-5.8%$0.985$0.985$0.91045,500
$0.979+0.006+0.6%$0.970$1.000$0.97043,200
$0.973-0.027-2.7%$0.970$0.992$0.97066,000
$1.000+0.006+0.6%$0.994$1.020$0.97092,900
$0.994+0.003+0.3%$1.000$1.020$0.971131,800
$0.991+0.006+0.6%$1.000$1.120$0.980202,600
$0.985-0.015-1.5%$1.000$1.020$0.98054,200
$1.000-0.030-2.9%$1.050$1.050$1.00050,100
$1.0300.0000.0%$1.050$1.067$1.03099,500
$1.030+0.020+2.0%$1.020$1.050$1.00080,600
$1.0100.0000.0%$1.000$1.040$0.990112,200
$1.010-0.010-1.0%$1.030$1.050$0.987238,500
$1.0200.0000.0%$1.030$1.040$0.99064,900
$1.020+0.020+2.0%$1.020$1.030$1.00075,200
$1.000-0.010-1.0%$1.020$1.050$0.990204,100
$1.010-0.020-1.9%$1.040$1.050$1.00078,500
$1.030+0.010+1.0%$1.040$1.060$1.010156,600
$1.020+0.021+2.1%$1.030$1.040$0.98879,500
$0.999-0.021-2.1%$1.000$1.020$0.97862,800
$1.020-0.010-1.0%$1.040$1.040$0.990114,500
$1.0300.0000.0%$1.030$1.050$1.01067,200
$1.030+0.020+2.0%$1.030$1.050$1.02594,400
$1.010-0.020-1.9%$1.030$1.030$0.98093,200
$1.0300.0000.0%$1.035$1.060$1.030138,200
$1.030-0.050-4.6%$1.070$1.080$1.020320,300
$1.080-0.030-2.7%$1.100$1.125$1.07586,600
$1.110-0.020-1.8%$1.140$1.140$1.090126,600
$1.130+0.030+2.7%$1.070$1.170$1.066240,000
$1.100+0.010+0.9%$1.080$1.110$1.055282,700
$1.090-0.040-3.5%$1.130$1.130$1.080250,200
$1.130+0.010+0.9%$1.120$1.150$1.11088,300
$1.120-0.080-6.7%$1.210$1.210$1.100242,600
$1.200+0.010+0.8%$1.180$1.220$1.170115,800
$1.190+0.020+1.7%$1.140$1.220$1.140270,145
$1.170-0.010-0.8%$1.190$1.210$1.130228,253
$1.180-0.030-2.5%$1.240$1.240$1.170138,300
$1.210+0.060+5.2%$1.160$1.220$1.100332,900

Splits

6 splits since 2013 · NASDAQ:PHIO · every price before a split is adjusted for it

DayRatioWhat
1-for-9Consolidation
1-for-12Consolidation
1-for-55Consolidation
1-for-10Consolidation
1-for-10Consolidation
1-for-30Consolidation
Ticker
NASDAQ:PHIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Phio Pharmaceuticals Corp. news

Phio Pharmaceuticals Corp. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
37 in the last 12 months · 189 in all · newest Nov 12, 2026 · oldest 2019
Decks
9 decks · latest Jan 6, 2023

Where Phio Pharmaceuticals Corp. is listed

ListingExchangeCountryCurrency
NASDAQ:PHIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PHIOBOATSUnited StatesUSD
Munich:44R1MunichGermanyEUR

Valuation

Price/book 0.9× against a median of 1.1×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.77M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.24

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Phio Pharmaceuticals Corp. · NASDAQ:PHIOUS$7.84M−US$2.77Mn/an/an/a0.9×n/a0.0×1.24
Intensity Therapeutics, Inc. · NASDAQ:INTSUS$8.19M−US$220,086n/an/an/a1.1×n/a0.0×1.30
Palatin Technologies, Inc. · AMEX:PTNUS$8.16MUS$4.58Mn/a12.7×n/a4.0×n/a0.1×0.61
Dare Bioscience, Inc. · NASDAQ:DAREUS$8.01M−US$2.65Mn/a−1.9×n/a3.4×−749.8%0.4×1.34
Cellectar Biosciences, Inc. · NASDAQ:CLRBUS$8.00M−US$15.05Mn/an/an/a0.4×n/a0.1×1.71
Immuron Limited · ASX:IMCUS$7.91MUS$1.94Mn/a0.4×n/a1.1×−49.8%0.0×n/a
Vivesto AB · OMXSTO:VIVEUS$7.76MUS$6.12Mn/an/an/a0.5×n/a0.0×n/a
Annexin Pharmaceuticals AB · OMXSTO:ANNXUS$7.59MUS$6.18Mn/an/an/a6.3×n/a0.0×n/a
Solvonis Therapeutics PLC · LSE:SVNSUS$7.57MUS$6.80Mn/an/an/a1.2×n/a0.0×n/a
Vistagen Therapeutics, Inc. · NASDAQ:VTGNUS$7.56M−US$11.87Mn/a−5.0×n/a0.5×n/a0.0×1.47
Noxopharm Ltd. · ASX:NOXUS$7.52MUS$10.36Mn/a11.0×n/an/a−312.2%n/an/a
Median of the othersUS$7.84MUS$3.26M0.4×1.1×−312.2%0.0×1.34

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
14.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.41 · 1 analyst

Team and board

Officers

OfficerRole
Robert BittermanPresident & Chief Executive Officer
Lisa CarsonChief Financial Officer
Greg YoungVP Corporate Services
Jennifer PhillipsSVP of Regulatory & Corporate Affairs
John M. ViglottiSVP Corporate Services
Kimberly ManVice President of Program Development and Strategic Planning

Board

DirectorRole
R. Todd PlottDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+0.2%
Q2 2026Aug 13, 2026+0.9%
Q1 2026May 7, 2026 · After close−6.1%
Q4 2025Mar 6, 2026+3.4%
Q3 2025Nov 13, 2025 · After close−9.1%
Q2 2025Aug 14, 2025 · After close−0.5%
Q1 2025May 15, 2025−1.1%
Q4 2024Mar 31, 2025 · After close−5.4%
Q3 2024Nov 14, 2024 · After close−0.9%
Q2 2024Aug 14, 2024 · After close−1.5%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 1, 2024 · After close+0.6%
Q4 2023Mar 20, 2024 · Before open+8.8%
Q3 2023Nov 9, 2023 · After close+5.9%
Q2 2023Aug 10, 2023 · After close−1.8%
Q1 2023May 11, 2023 · After close−10.1%
Q4 2022Mar 22, 2023 · After close+8.2%
Q3 2022Nov 10, 2022 · After close−11.1%
Q2 2022Aug 11, 2022 · After close−3.6%
Q1 2022May 12, 2022 · After close+2.3%
Q4 2021Mar 22, 2022 · After close+4.4%

Open Events

Decks

Open Decks

Financings

RaiseDate
Warrant exercise of shares of common stock on exercise of existing warrants, with new unregistered warrants
Tranche closed: US$11.5M raised · US$2.05 a share · Warrants at US$2.05 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and, primarily, accelerated development activities for the next clinical phase of PH-762 for cutaneous carcinomas
Nov 13, 2025
Registered direct offering of common stock with concurrent private placement warrants
Closed: US$1.83M raised · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes, including the Phase 1b trial of PH-762 and development of PH-894
Jan 21, 2025
Warrant exercise of warrants issued July 12, 2024
Closed: US$2.9M raised · US$5.45 a share
Jan 21, 2025
Registered direct offering of common stock with concurrent private placement warrants
Announced: US$2.5M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Jan 15, 2025
Registered direct offering of common stock with concurrent private placement warrants
Announced: US$3.19M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Jan 14, 2025
Registered direct offering of common stock with concurrent private placement warrants
Announced: US$480,000 · US$2 a share · Warrants at US$2 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Dec 23, 2024
Registered direct offering of common stock with concurrent private placement warrants
Announced: about US$1.15M · US$2.635 a share · Warrants at US$2.51 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Dec 19, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000021.0K138.0K15.0K19.0K
Cost of revenue4.62M3.64M6.33M193.0K192.0K3.72M4.30M4.33M5.37M5.42M
Gross profit-4.62M-3.64M-6.33M-193.0K-192.0K-3.72M21.0K138.0K-5.36M-5.40M
Research and development4.62M3.64M6.33M7.01M8.89M3.72M4.30M4.33M5.37M5.42M
Selling, general and administrative4.60M3.74M4.29M4.45M4.63M5.08M4.71M3.18M4.01M3.62M
Operating income-9.22M-7.39M-10.8M-11.5M-13.5M-8.79M-8.99M-7.36M-14.1M-9.02M
Depreciation and amortization3.00K2.00K56.0K71.0K75.0K72.0K67.0K81.0K70.0K53.0K
EBITDA-9.22M-7.38M-10.8M-11.4M-13.4M-8.72M-8.92M-7.28M-14.0M-8.96M
Interest expense231.0K175.0K9.00K0001.00K0
Income before tax-8.70M-7.15M-10.8M-11.5M-13.3M-8.79M-8.91M-7.36M-14.1M-8.99M
Income tax00000000-1.62M0
Net income-8.70M-7.15M-10.8M-11.5M-13.3M-8.79M-8.91M-7.36M-12.5M-8.99M
Earnings per share, basic-1.45-9.08-46.76-10.10-12.43-1.92-19.33-57.46-5.52-16.41
Earnings per share, diluted-9.08-46.76-10.10-12.43-1.92-19.33-57.46-5.52-16.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents21.0M5.38M8.49M11.8M24.1M14.2M6.93M14.9M3.58M12.9M
Short-term investments50.0K0
Current assets21.5M5.74M9.32M12.4M24.7M15.2M7.30M15.2M3.83M13.1M
Property, plant and equipment11.0K2.00K6.00K183.0K133.0K157.0K210.0K172.0K248.0K114.0K
Total assets21.5M5.74M9.36M12.8M25.2M15.7M8.04M15.3M4.10M13.4M
Accounts payable435.0K253.0K657.0K779.0K283.0K728.0K809.0K550.0K511.0K917.0K
Current liabilities435.0K1.01M1.63M1.94M3.07M2.20M1.88M1.74M2.27M2.54M
Long-term debt0231.0K0
Total debt35.0K170.0K0231.0K0
Total liabilities1.34M1.01M1.63M1.97M3.24M2.72M2.29M1.74M2.27M2.54M
Shareholders' equity20.1M4.72M7.73M10.8M21.9M13.0M5.75M13.6M1.83M10.9M
Shares outstanding11.6M1.73M416.4K1.14M1.13M5.78M669.4K342.6K2.43M1.30M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-7.98M-7.11M-10.7M-12.1M-11.9M-8.80M-8.64M-7.52M-9.51M-7.76M
Capital spending-12.0K-1.00K-5.00K-121.0K-51.0K-19.0K-72.0K-5.00K-203.0K-4.00K
Free cash flow-7.99M-7.11M-10.8M-12.3M-11.9M-8.82M-8.72M-7.53M-9.72M-7.76M
Cash from investing-12.0K8.00K-5.00K-121.0K-51.0K-19.0K-72.0K-5.00K-103.0K5.35M
Cash from financing23.6M4.00M7.41M-26.0K21.7M16.1M772.0K18.8M292.0K10.2M
Dividends paid-4.09M-1.00K
Share buybacks0-1.00K-11.0K-28-1-15.0K1.00K3.00K2.00K10.2M
Change in cash15.6M-3.11M-3.34M-12.3M9.81M7.31M-7.95M11.3M-9.32M7.79M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 13, 2026Current reportSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 28, 2026Offer documentSEC
8-K · Current reportSep 28, 2026Management or board changeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
8-K · Current reportSep 14, 2026Current reportSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
ARS · Annual report to shareholdersAug 14, 2026Annual reportSEC
DEFA14A · Additional proxy materialAug 14, 2026Meeting noticeSEC
DEF 14A · Proxy statementAug 14, 2026Meeting noticeSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
8-K · Current reportJul 21, 2026Management or board changeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
8-K · Current reportApr 8, 2026Material contractSEC
424B5 · ProspectusApr 8, 2026Offer documentSEC
8-K · Current reportMar 30, 2026Current reportSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
8-K · Current reportFeb 18, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 10, 2026Current reportSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
8-K · Current reportJan 20, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 23, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 11, 2025Big-stake noticeSEC
424B3 · ProspectusDec 4, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 4, 2025Other filingsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
8-K · Current reportNov 25, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 24, 2025Big-stake noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
S-3 · Registration statementNov 20, 2025Offer documentSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
DNov 12, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2025Big-stake noticeSEC
8-K · Current reportNov 6, 2025Material contractSEC
8-K · Current reportNov 3, 2025Current reportSEC
8-K · Current reportOct 31, 2025Management or board changeSEC
4/A · Change in ownership, amendedSep 15, 2025Insider tradeSEC
8-K · Current reportSep 15, 2025Management or board changeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
S-8 · Registration statement for employee plansSep 11, 2025Offer documentSEC
8-K · Current reportSep 3, 2025Current reportSEC
DEFA14A · Additional proxy materialAug 28, 2025Meeting noticeSEC
424B3 · ProspectusAug 27, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
CORRESP · Letter to the SECAug 21, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 21, 2025Other filingsSEC
S-3 · Registration statementAug 14, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
DAug 4, 2025Other filingsSEC
8-K · Current reportJul 30, 2025Material contractSEC
ARS · Annual report to shareholdersJul 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialJul 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementJul 30, 2025Meeting noticeSEC
8-K · Current reportJul 25, 2025Current reportSEC
8-K · Current reportJul 7, 2025Current reportSEC
8-K · Current reportJun 25, 2025Current reportSEC
3 · Initial statement of ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Management or board changeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportMay 7, 2025Current reportSEC
8-K · Current reportApr 22, 2025Current reportSEC
8-K · Current reportApr 9, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
3 · Initial statement of ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportFeb 20, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
424B3 · ProspectusJan 29, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 29, 2025Other filingsSEC
DJan 28, 2025Other filingsSEC
DJan 28, 2025Other filingsSEC
DJan 28, 2025Other filingsSEC
CORRESP · Letter to the SECJan 27, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 24, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeJan 23, 2025Big-stake noticeSEC
S-1 · Registration statementJan 21, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 17, 2025Big-stake noticeSEC
8-K · Current reportJan 17, 2025Material contractSEC
424B5 · ProspectusJan 17, 2025Offer documentSEC
8-K · Current reportJan 15, 2025Material contractSEC
424B5 · ProspectusJan 15, 2025Offer documentSEC
8-K · Current reportJan 14, 2025Material contractSEC
424B5 · ProspectusJan 14, 2025Offer documentSEC
8-K · Current reportJan 13, 2025Current reportSEC
DJan 7, 2025Other filingsSEC
DJan 3, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeDec 27, 2024Big-stake noticeSEC
8-K · Current reportDec 26, 2024Material contractSEC
SCHEDULE 13G · Big-stake noticeDec 26, 2024Big-stake noticeSEC
424B5 · ProspectusDec 23, 2024Offer documentSEC
8-K · Current reportDec 20, 2024Material contractSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
8-K · Current reportDec 19, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024Current reportSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
424B3 · ProspectusAug 5, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 2, 2024Other filingsSEC
8-K · Current reportAug 1, 2024Management or board changeSEC
CORRESP · Letter to the SECJul 30, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 29, 2024Other filingsSEC
S-1 · Registration statementJul 26, 2024Offer documentSEC
8-K · Current reportJul 24, 2024Current reportSEC
DJul 23, 2024Other filingsSEC
8-K · Current reportJul 12, 2024Material contractSEC
8-K · Current reportJul 5, 2024Current reportSEC
8-K · Current reportJul 2, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 2, 2024Other filingsSEC
CORRESP · Letter to the SECJun 27, 2024Other filingsSEC
8-K · Current reportJun 21, 2024Management or board changeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportMay 28, 2024Current reportSEC
UPLOAD · Letter from the SECMay 24, 2024Other filingsSEC
S-3 · Registration statementMay 20, 2024Offer documentSEC
RW · Request to withdraw a registrationMay 20, 2024Other filingsSEC
S-1 · Registration statementMay 17, 2024Offer documentSEC
424B5 · ProspectusMay 17, 2024Offer documentSEC
8-K · Current reportMay 17, 2024Material contractSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialMay 8, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 8, 2024Meeting noticeSEC
ARS · Annual report to shareholdersMay 8, 2024Annual reportSEC
PRE 14A · Preliminary proxy statementApr 22, 2024Meeting noticeSEC
8-K · Current reportApr 2, 2024ResultsSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
8-K · Current reportJan 26, 2024Current reportSEC
424B3 · ProspectusDec 28, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 28, 2023Other filingsSEC
CORRESP · Letter to the SECDec 22, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 21, 2023Other filingsSEC
S-1 · Registration statementDec 19, 2023Offer documentSEC
DDec 19, 2023Other filingsSEC
8-K · Current reportDec 8, 2023Material contractSEC

This page holds 200 of 900 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Phio Pharmaceuticals Corp.’s releases · as of Nov 3, 2026

Common shares
11,951,632
Fully diluted
11,951,632

Fully diluted

LineSharesAs of
Common shares11,951,632Nov 3, 2026

Warrants and options

Lot
Warrants · US$2.05 · expire about Nov 2027
Warrants · US$3.00 · expire about Jan 2027

Share count over time

CountShares
Nov 3, 202611,951,632

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard170K1.4%US$175KSep 30, 2026
Geode Capital106K0.88%US$109KSep 30, 2026
Two Sigma68,4160.57%US$70,469Sep 30, 2026
Citadel65,6860.55%US$67,657Sep 30, 2026
Bridgeway Capital Management, LLC62,0000.52%US$63,860Sep 30, 2026
Jane Street61,4460.51%US$63,289Sep 30, 2026
Renaissance Technologies57,3770.48%US$59,098Sep 30, 2026
Nomura50,0000.42%US$51,500Sep 30, 2026
Cetera Investment Advisers47,5000.40%US$48,925Sep 30, 2026
XTX Topco Ltd27,8210.23%US$28,656Sep 30, 2026
All 24 holders
HolderSharesOf the companyValueAs of
Northern Trust25,0510.21%US$25,803Sep 30, 2026
Hrt Financial LP21,4850.18%US$22,000Sep 30, 2026
StoneX Group Inc.11,1440.09%US$11,455Sep 30, 2026
Morgan Stanley6,0000.05%US$6,180Sep 30, 2026
UBS3,0700.03%US$3,162Sep 30, 2026
Osaic Holdings, Inc.2,0000.02%US$2,060Sep 30, 2026
Spire Wealth Management2,0000.02%US$2,060Sep 30, 2026
Tower Research Capital LLC (TRC)1,6800.01%US$1,730Sep 30, 2026
SBI Securities Co., Ltd.1,2470.01%US$1,284Sep 30, 2026
Assetmark, Inc110<0.01%US$113Sep 30, 2026
Activest Wealth Management9<0.01%US$9Sep 30, 2026
Caitong International Asset Management Co., Ltd3<0.01%US$3Sep 30, 2026
Fidelity3<0.01%US$3Sep 30, 2026
Barclays2<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund94,2620.79%US$96,619Jun 30, 2026
Fidelity Extended Market Index Fund80,5990.67%US$89,465May 31, 2026
Nomura Healthcare Fund50,0000.42%US$51,250Jun 30, 2026
Fidelity Series Total Market Index Fund14,6640.12%US$16,277May 31, 2026
Fidelity Total Market Index Fund13,2850.11%US$14,746May 31, 2026
Ultra-Small Company Fund12,0000.10%US$12,300Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund4<0.01%US$4Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Deming David H
Director
Buy3,000USD 0.83US$2,500Nov 13, 2026
Deming David H
Director
Buy9,000USD 0.81US$7,322Nov 12, 2026
Deming David H
Director
Buy5,200USD 0.84US$4,358Nov 11, 2026
Deming David H
Director
Buy6,800USD 0.84US$5,709Nov 10, 2026
Bitterman Robert J
Director, Officer: Chairman, Pres. & CEO
Buy25,000USD 0.82US$20,500Nov 9, 2026
Plott Ronald Todd
Director
Buy18,300USD 0.83US$15,189Nov 9, 2026
Plott Ronald Todd
Director
Buy5,000USD 1.04US$5,200Sep 29, 2026
Plott Ronald Todd
Director
Buy5,000USD 1.03US$5,150Sep 28, 2026
Bradford Patricia A
Director
Buy6,500USD 1.01US$6,565Sep 24, 2026
Bitterman Robert J
Director, Officer: Chairman, Pres. & CEO
Buy2,000USD 1.03US$2,060Sep 22, 2026
All 14 trades
TradeTradeSharesPriceValueDate
Bradford Patricia A
Director
Buy12,000USD 1.03US$12,360Sep 15, 2026
Plott Ronald Todd
Director
Buy15,000USD 1.14US$17,100Aug 19, 2026
Bitterman Robert J
Director, Officer: Chairman, Pres. & CEO
Buy10,000USD 1.06US$10,600Aug 18, 2026
Bitterman Robert J
Director, Officer: Chairman, Pres. & CEO
Buy10,000USD 0.99US$9,900Jun 26, 2026

Big stakes

StakeStakeSharesDateFiling
CVI Investments, Inc.9.90%1.33MSep 30, 2026Schedule 13G
Mitchell P. Kopin9.10%1.14MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Deming
Other companies: Better for You Wellness Inc. (Director · Since at least Sep 30, 2021); Sorrento Therapeutics, Inc. (Director · Jul 11, 2016 – Sep 15, 2017 · Past); Albany Molecular Research Inc (Director · Jun 15, 2016 – Aug 31, 2017 · Past)
Director · Since at least Feb 19, 2025
Keith L Brownlie
Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 15, 2017); Cancer Genetics Inc (Director · Jul 24, 2013 – May 22, 2014 · Past); Soligenix, Inc. (Director · Jun 21, 2012 – Sep 27, 2018 · Past)
Director · Mar 1, 2013 – Feb 13, 2019 · Past
Curtis Lockshin
Other companies: Xenetic Biosciences, Inc. (Chief Sciencific Officer · Dec 4, 2019 – Dec 11, 2023 · Past)
Director · Since at least Mar 1, 2021
Geert CauwenberghDirector · Mar 1, 2013 – Feb 17, 2023 · Past
Greg YoungVP Corporate Services · Since at least Oct 6, 2026
H Paul DormanDirector · Apr 18, 2013 – Feb 15, 2022 · Past
Jennifer PhillipsSVP of Regulatory & Corporate Affairs · Since at least Oct 19, 2026
John M. ViglottiSVP Corporate Services · Since at least Mar 10, 2026
Jonathan E FreemanDirector · Since at least Sep 11, 2024
Kimberly ManVice President of Program Development and Strategic Planning · Since at least Feb 23, 2026
All 16 people
PersonSeat
Lisa CarsonChief Financial Officer · Since at least Feb 19, 2026
Pamela PavcoChief Development Officer · Dec 16, 2016 – Feb 1, 2017 · Past
Patricia A BradfordDirector · Since at least Sep 11, 2025
Robert BittermanPresident & Chief Executive Officer · Since at least Sep 29, 2026
Robert L FerraraDirector · Since at least May 20, 2025
R. Todd PlottDirector · Since at least Jul 21, 2026

Open People

Log in to ask 6ix AI your own questions about Phio Pharmaceuticals Corp.